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Background: Rosette-formation of Plasmodium falciparum parasitized erythrocytes is of importance in the
development of severe malaria. The parasite-derived molecule PfEMP1 (Plasmodium falciparum erythrocyte membrane
protein 1), central to rosetting, is suggested to be included in a multimeric vaccine targeting severe disease.
Methods: Three recombinant NTS-DBL1α-domains of PfEMP1 were generated in Escherichia coli, purified and used for
immunization of rats and goats. Antibody titres were determined in ELISA assays and responses were compared
in-between different individual animals and species. Reactivity with the parasites was tested in live pRBC using FACS.
B-cell epitopes prediction was carried out in silico and compared to the results obtained by peptide microarray.
Screening for serological cross-reactivity with heterologous NTS-DBL1α variants was carried out by ELISA, peptide array
and FACS on pRBC of different laboratory strains and patient isolates.
Results: All three NTS-DBL1α-domains induced high titres of antibodies that were biologically active with no apparent
difference between constructs covering slightly different parts of the DBL1α-sequence. The different animal species
showed comparable titres of antibodies, while variations within individuals of the species could be observed.
Mapping of the recognized epitopes revealed that most parts of the molecule were able to induce an antibody
response with a tendency for the N and C terminal parts of the molecule for slightly higher recognition. Important
differences to the epitopes predicted were found as some of the most conserved parts of the DBL1α-domain
contained the main epitopes for antibody reactivity. ELISA assays and peptide microarray demonstrated substantial
cross-reactivity to heterologous variants, while binding to native PfEMP1 was observed only in few combinations on
the pRBC surface, underlining that mainly internal, conserved and not surface exposed parts of the DBL1α-domain are
responsible for this observation.
Conclusion: Biologically active antibodies can be induced consistently, with high titres, in different animal species and
the antibodies elicited by different constructs react with similar epitopes. Induced antibodies recognize epitopes
localized in all subdomains of the DBL1α-sequence. Cross-reactivity between NTS-DBL1α-variants is common in ELISA,
but rare with live pRBC emphasizing that also internal, conserved areas of PfEMP1 carry important highly immunogenic
epitopes of the molecule.
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Rosetting, the binding of parasitized to non-parasitized
red blood cells (RBC), has been described as an important
virulence factor of the Plasmodium falciparum parasite.
Rosetting has been found associated with severe malaria
in many studies in Africa [1-8], has been described to lead
to microvascular obstruction [9,10] and has been sug-
gested as one of the most important factors bringing about
severe disease [11,12].
During rosetting, the parasite ligand P. falciparum ery-
throcyte membrane protein 1 (PfEMP1) binds serum pro-
teins and receptors on the human RBC surface. So far,
serum proteins, such as non-immune immunoglobulins,
fibrinogen and albumin as well as blood group A and B
antigen, heparan sulphate [13-18] and the complement re-
ceptor 1 (CR1) [19,20] have been identified to be involved
in the rosetting phenomena.
The PfEMP1 protein family is the by far best character-
ized group of parasite ligands linked to the parasite’s
capacity to cytoadhere [21-23] and rosette [19,24,25], how-
ever other molecules have been suggested to be involved
in these adhesive events. PfEMP1 proteins share a com-
mon structure of tandemly arranged Duffy Binding Like
domains (DBL) and Cysteine-rich InterDomain Regions
(CIDR). PfEMP1 vary in size between 200–400 kDa and
are encoded by a repertoire of around 60 var genes per
genome [26] responsible for the antigenic variation at the
pRBC surface [27-29].
The N-terminal NTS-DBL1α-domain of the PfEMP1
molecule is central in the binding event to host RBC
[15,19,24,30]. To date, three different NTS-DBL1α-variants
involved in rosetting have been analysed in detail:
NTSDBL1α-R29var1 [19], NTSDBL1α-PAvarO [24] and
NTSDBL1α-FCR3S1.2var2 [25]; all three variants are enco-
ded by group A var genes. This observation based on para-
site laboratory strains is supported in P. falciparum patient
isolates, where a correlation between rosetting and the
transcription of group A var genes exists [31-34].
Although a central role of the variant PfEMP1 molecule
in the acquisition of malaria protective antibodies has
been underlined in a number of studies [35-45], few have
specifically investigated anti-rosetting antibodies. There is
the indication that antibodies able to disrupt rosettes are
involved in protection against severe disease [1,2] and
antibodies targeting domains involved in rosetting can
promote the opsonization of the pRBC [46-48]. Further,
polyclonal antibodies towards the rosette-associated
DBL1α-domains have been shown to be able to disrupt
rosettes of the homologous [19,24,25] and recently also of
heterologous parasite strains [46], generating conflicting
data whether epitopes exposed by rosetting pRBC are vari-
ant specific [49] or shared by parasites displaying a similar
adhesive phenotype [46]. In addition, there is to date no
information available about which epitopes are targeted bythese antibodies and where they are located within the
molecule. PfEMP1-variants linked to rosetting are, due to
the strong association between rosetting and severe dis-
ease, promising vaccine candidates. The development of a
vaccine based on a recombinant domain derived from
PfEMP1 needs to be initiated with the detailed analysis of
the vaccine-induced protective immune response in an
animal model, even though immunological responses in
such models are often only indicative of what will be
observed in the human host.
This study reports the generation of antibodies against
three NTS-DBL1α-domains in two different animal spe-
cies, and the comparison of their antigenicity and serum
titres induced by the antigens. Antibodies were found to
be biologically active and were mapped for their specific
epitopes in peptide microarrays. Detailed analysis of their
capacity to cross-react with other DBL1α-variants was car-
ried out both in regard to linear epitopes as well as epi-
topes displayed by the native protein on the pRBC surface.
Methods
Parasite cultures
Culture of P. falciparum laboratory clones/strains was
carried out according to standard methods [50], while
the protocol was slightly modified for patient isolates
[51]. Seven different patient isolates, collected in Uganda
[8] were used in this study (UKS111, UKS31, UKS221,
UAS22, UKM62, UAM51 and UAM15). For the main-
taining of the rosetting phenotype of FCR3S1.2, R29 and
PAvarO enrichment with monoclonal antibodies was
performed [24].
Production of recombinant protein
Expression constructs of the three His-tagged NTS-
DBL1α domains used here was performed as described
[52]. For IT4var60 the expression was carried out in
Escherichia coli Shuffle T7 express: bacteria were grown at
30°C till OD600 = 0.6 and subsequently induced with 0.4
mM IPTG for 20h at 16°C. Pelleted cells were first sub-
jected to osmotic shock, as described [53], and subse-
quently lysed by sonication. The soluble part, containing
the recombinant protein, was separated by centrifugation
at 12,000 g for 15 min and subsequently purified.
For IT4var9 and PAvarO, BL21 (DE3) bacteria were
grown till OD600 = 0.8. Culture was induced for 3 h at
37°C with 0.1 mM IPTG. Following induction the cells
were lysed by sonication, crude inclusion bodies were
pelleted upon centrifugation at 12,000g for 30 min and
solubilized in denaturing solution (6M Guanidine HCl,
50mM Tris–HCl pH 8, 100mM NaCl, 10mM EDTA pH
8, 10 mM DTT) overnight at +4°C. The recombinant
proteins were refolded by the method of rapid dilution:
the protein solution was filtered and added dropwise to
ice-cold refolding solution (200 mM Tris–HCl pH 8,
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3.7mM cystamine) to a final concentration of 0.2 mg/ml.
Refolding was allowed to proceed at +4°C for 36 h.
The recombinant DBL1α-domains were then dialysed to
remove the excess of arginine and EDTA and concentrated
using Amicon Ultracel centrifugal filter units (Millipore).
All proteins were purified by Immobilized Metal Affinity
Chromatography over TALON Cobalt column (Clontech),
eluted with 200mM imidazole and further purified to
homogeneity by size exclusion chromatography on a
HiLoad 16/60 Superdex 75pg colum (GE-Healthcare).Generation of antibodies in goats and rats
Polyclonal antibodies were produced in goats commer-
cially by Agrisera (Vännäs, Sweden). Animals were
immunized four times at one-month intervals with 200
μg of protein; the protein was emulsified in Freund’s
complete for the first immunization and incomplete ad-
juvant for the following three immunizations. Final
bleeding was carried out two weeks after the last
immunization. In addition, α-NTS-DBL1α-sera gener-
ated in earlier studies [25,54] were used. Briefly, sera
against the NTS-DBL1αS1.2var1, 3d7var5.2, PAvarO (mixed)
and NTS-DBL1αS1.2var1, 3d7var5.2, PAvarO (sequential)
were generated in rats by immunization with SFV-
particles on day 0, 30 and 60 (1×108 particles/rat) and
with recombinant protein emulsified in Montanide ISO
720 (Seppic, France) on day 90 (100 μg protein/rat) sub-
cutaneously [54]. Further, rat sera against the NTS-
DBL1αIT4var60 [25] and the NTS-DBL1α T4var9 were
generated by immunizing rats trice with 100μg his-
tagged recombinant NTS-DBL1-protein emulsified in
Freund’s complete (first immunization), respectively in-
complete adjuvant (second, third immunization).Ethics statement
The animal studies were approved by the Swedish Board
of Agriculture (permission rats: N237/07, N103/10;
goats: A37/10).ELISA
Reactivity of the generated antibodies with recombinant
protein was tested in ELISA assays as described [30];
briefly plates were coated with 2 μg/ml protein over-
night, subsequently blocked and thereafter incubated
with 100 μl antibody containing solution in serial two-
fold dilutions between 10 to 0.001 mg/ml. Reactivity was
visualized using an ALP-coupled antibody against the
corresponding species; pre-immune serum (rat) or pre-
immune goat IgG was used as a control for background
binding in all experiments.Analysis of surface reactivity of pRBC by flow cytometry
Analysis of surface reactivity was carried out as described
[52], briefly, pRBCs of ≈ 24-30h p.i. were incubated with
goat IgGs (final concentration 10 μg/ml), or rat sera (final
dilution 1:10). Non-immune goat IgG, respectively rat pre-
serum in the same concentration was used as control
in all experiments; reactivity was visualized with an
ALEXA488-coupled, species specific secondary antibody
(dilution 1:100), nuclear staining was performed with eth-
idium bromide at 2.5 μg/ml and cell acquisition done with
a flow cytometry (FACSCalibur, BD Bioscience), 5000
pRBC counted, the analysis was performed using FlowJo
software. For analysis of surface cross-reactivity, pRBC
incubated with the fluorophore-labelled secondary anti-
body only were used to define the non-reactive cell popu-
lation; the percentage of positive cells was thereafter
determined in all samples. Samples were considered posi-
tive for surface reactivity, when the percentage of positive
cells was at least twice as high as the corresponding nega-
tive control; reactivity was scored as follows: low reactivity:
2-5× higher than control; medium reactivity: 5-105×
higher than control; high reactivity ≥105× higher than
control.
Prediction of B cell epitopes
Prediction of B cell epitopes was carried out by submitting
the protein sequences to Bepipred server [55]. Cut-off for
posivity was set to 0.5.
Peptide array
Peptide microarrays were manufactured by JPT (JPT
Peptide Technologies, Berlin, Germany) with each slide
contained three identical subarrays of a large set of over-
lapping amino acids of DBL1α-domains of five labora-
tory strains.
Slides were incubated for 16 h at 4°C in with 5 ug/ml
of the antibody of interest in PBS buffer containing 3%
of FCS and 0.5% of Tween (TPBS). After washing twice
with TPBS and trice with distilled water, incubation with
a Cy5-labelled secondary antibodies (Jackson Immuno-
Research) was carried out; followed by washing steps.
Slides were scanned at 635nm using a GenePix 4000B
microarray scanner (Axon Instruments, CA, USA) and
images analyzed using GenePixPro 7.0 software in com-
bination with the GAL file provided by JPT. The mean
of fluorescence intensity obtained from the foreground
and the local background were used to calculate the
antibody responses; data presented here correspond to
the average of the three subarrays.
Results
Expression of recombinant NTS-DBL1α in Escherichia coli
Recombinant NTS-DBL1α domains of group A rosette-
mediating PfEMP1 IT4var60 [25], IT4var9 [19] and
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binant proteins in E. coli (Figure 1A). Initial attempts
resulted in insoluble proteins that aggregated in inclusion
bodies. Proteins were subsequently refolded and purified,
giving a final yield of 0.5 to 3 mg per litre. For NTS-
DBL1α of IT4var60 further optimization trials were car-
ried out by re-designing the domain boundaries and
testing several expression strains. The construct spanning
from amino-acids 1 to 481 expressed in E. coli Shuffle T7
express with overnight induction at 16°C gave the highest
yield of soluble protein with about 10 mg per litre of bac-
terial culture. All protein ran at the expected size of
monomer under non-reducing conditions and showed a
single, gaussian shaped peak, when run on size exclusion
column (Figure 1B).
Antigenicity of distinct NTS-DBL1α domains in different
animal species
To examine the levels of antigenicity of different recom-
binant NTS-DBL1α domains, associated with a rosetting
phenotype, different animals were immunized and their
IgG levels compared using ELISA. NTS-DBL1αIT4var60
and NTS-DBL1αIT4var9 were used to immunize one goat
and three rats respectively, while NTS-DBL1αPAvarO was
used only for one goat immunization. All immunizations
produced antibodies with a sigmoidal dose–response curve
typically seen in antibody titration (Figure 2). Variation in
antibody titres between animals of the same specie to dis-
tinct domains were minimal and probably not due to in-
trinsic differences in the protein immunogenicity by itself
but rather to individual variation in the capacity of theFigure 1 Characterization of the recombinant NTS-DBL1α domains. A
stained with Coomassie-Blue. Two μg of protein were run under non-reduc
NTS-DBL1α domains. The proteins were run on Superdex75 HR 10/30 to ch
and green respectively.immunized animal to generate immune response. In
addition, no significant difference was detected in titres be-
tween animals immunized with shorter and refolded
domains (PAvarO, ITvar9) versus the ones immunized with
the longer construct, secreted as soluble protein in E. coli
(ITvar60) (Figure 2).
Comparison of titres between different animal species
revealed no difference in antibody titres towards the
same protein. In order to compare purified IgG obtained
from goats with rat sera a concentration of 10 mg of
IgG per ml of serum in the immunized animal was
assumed and the concentration calculated accordingly. It
is likely that the individual levels are variable around this
value, explaining the larger variation between different
rats as compared to goats (Figure 2B).
In summary, all recombinant domains tested herein
produced high titres of antibodies in immunized ani-
mals, suggesting that both rats and goats are good mod-
els to study immune responses to those domains,
especially considering the low level of background seen
with pre-immune sera/IgG.
Antibody reactivity against native PfEMP1 displayed on
the surface of parasitized erythrocytes
All antibodies were tested for their ability to recognize
native full-length PfEMP1 expressed on the surface of
pRBC. Parasites cultures were maintained as monovariant
as previously described [24] and tested by flow cytometry
for recognition by the antibodies generated.
In line with the ELISA titres results, no difference was
detected in the capacity to recognize the surface of: Recombinant NTS-DBL1α domains run on 12% SDS-PAGE gel and
ing conditions. B: Size exclusion profiles of the recombinant
eck homogeneity. IT4var60, PAvarO and IT4var9 are in blue, red
Figure 2 ELISA titration of the generated antibodies. Serial
two-fold dilution of the generated antibodies in goat (A) or rat (B)
towards the homologous NTS-DBL1α domains. Plates were coated
with protein at 2 μg/ml and antibodies assayed at different
concentration. For the rat sera the concentration was estimated
assuming 10mg of IgG in 1ml of serum.
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antibodies (Figure 3 and [52]); all antibodies tested la-
belled the pRBC population expressing the homologous
PfEMP1-variant. Further, there was no difference be-
tween Abs generated by immunization with shorter and
refolded versus longer, soluble protein.NTS-DBL1α B cell epitope prediction
Epitopes exposed on the surface of the proteins and ac-
cessible to IgG were predicted using the BepiPred server
[55]. For all three the proteins analysed 11 major antige-
nic areas were identified that were largely overlapping
(Figure 4). Most of the predicted epitopes were spanning
surface-exposed loop regions, according to the crystal
structure of PAvarO and the molecular models of
IT4var60 and IT4var9. The only epitope predicted to be
targeting an α-helical structure is localized at the end of
helix-7 of NTS-DBL1α, a region that has been previouslyshown not to be surface exposed on the full length
PFEMP on the pRBC surface [52]. The loop of subdomain
3 (SD3), shown to be a target in anti-rosetting activity
[52], is also consistently predicted as B-cell epitope.
Mapping of epitopes by peptide array
Antibodies of all immunized goats and rats were tested
on a peptide array holding five complete NTS-DBL1α
sequences, in order to investigate homologous and cross-
reactive responses in different animals. Each sequence was
covered by approximately 100 15-mer peptides overlap-
ping by four.
Firstly the responses towards the homologous sequences
was analysed in order to identify converge and divergence
in peptide recognition between different animal species.
IgG reactivity of the goat was compared with average re-
activity of the three immunized rats for IT4var60 and
IT4var9 (Figure 5A-B).
For IT4var9, the reactivity of antibodies produced in rats
was high for most parts of the protein; highest reactivity
was found in the NTS and subdomain 1 (SD1) region of
the molecule. The goat IgG showed a similar pattern of
response with differences just in the amplitude of the re-
sponse but not in the areas recognized (Figure 5B).
IT4var60 immunization showed a tendency of a higher
response of goat IgG towards peptides localized in NTS
and SD1 while rat antibodies responded better to the
SD3 area (Figure 5A).
When comparing the reactivity of goat IgG obtained
from immunization with distinct protein it was not pos-
sible to detect any consistent pattern in the epitope recog-
nition (Additional file 1) with very different patterns
between different animals. However, there was a general
tendency that the N and C terminal parts of the molecules
were more recognized by the antibodies.
Goat IgG was also analysed for the capacity of cross-
recognizing peptides present on other proteins (Additional
file 2). Very few peptides were cross-recognized, in line
with the known difficulties of generating cross-reactive
antibodies, all goats consistently recognized the conserved
peptide LARSFADIG in all the NTS-DBL1α sequences
tested. Immunizations with both IT4var9 and PAvarO
generated antibodies that strongly recognized several
sequences on the peptide array corresponding to the
IT4var60 sequence: in particular, epitopes in SD1 and SD2
showed higher recognition by the IgG from PAvarO-goat
as compared to the homologous IT4var60-goat (Additional
file 2A).
Cross-reactivity screening by ELISA and FACS
The generated antibodies were subsequently tested for
their capacity to cross-react with heterologous NTS-
DBL1α domains both by ELISA and by FACS (Figures 6
and 7). In ELISA cross-recognition of heterologous
Figure 3 Antibody reactivity against the native, surface expressed homologous PfEMP1. Surface reactivity of rat sera with homologous
pRBC as detected by Alexa488-conjugated secondary antibody and visualized by flow cytometry. Immune and non-immune controls are in blue
and red respectively.
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of cross-reactive antibodies were high (Figure 6). Further
cross-reactivity on linear peptides could be observed by
analysis of the peptide array (Additional file 2). For ex-
ample, goat anti-PAvarO IgG, which reacted with many
peptides of IT4var60, had high recognition of the latter
protein with a titre just slightly lower as compared to
homologous protein (Figure 6C). Goat anti-IT4var60 IgG,
on the other hand, showed some level of cross-recognition
but with much lower titres as compared to homologous
domain, as seen by the poor recognition of other peptides
in the array (Figure 6A and Additional file 2).
Subsequently, the surface cross-reactivity of the anti-
bodies was studied with pRBC of 15 different parasitesFigure 4 B cell epitope prediction of the studied sequences. B cell epi
sequences of IT4var60 (black), IT4var9 (red) and PAvarO (blue). Values abovincluding laboratory clones/strains and patient isolates.
The antibodies were tested by flow-cytometry for their
ability to recognize the surface of RBCs parasitized with
heterologous parasite strains and correlated those data
with ELISA and peptide-array data. Goat IgGs were used
at 10μg/ml while rat sera was diluted 1:5 and 1:10. The
homologous pRBC always displayed strong reactivity.
However, binding to heterologous pRBC was observed
only in a few combinations (Figure 7). Goat anti-IT4var60
displayed surface cross-reactivity with pRBCs of R29. Sur-
prisingly the goat anti-PAvarO did not cross-react with
FCR3S1.2, expressing IT4var60, despite the high number
of peptides recognized in the array, suggesting that those
specific area of the molecule might be hidden on fulltopes were predicted using the Bepipred server for the NTS-DBL1α
e 0.5 are considered as predicted epitopes.
Figure 5 Analysis of epitope recognition by peptide microarray. Antibodies generated in goats (blue) and rats (black) were tested for
peptide recognition against the homologous sequences on a 15-mers peptide array. For IT4var60 (A)*, IT4var9 (B) and PAvarO (C) goat IgG were
tested at 1μg/ml while rat sera at 1:100 dilution. Shown is the average of the individual animals immunized with the same protein. Results are
expressed as arbitrary absorbance units normalized to the highest value set as 100%. *Data for goat IgG are also presented in [52].
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single DBL1α-domain displayed surface cross-reactivity;
however, low or moderate cross reactivity was observed
against two laboratory and one patient isolate with rat sera
against a mixture of three DBL1α-domains (Figure 7).Discussion
The NTS-DBL1α domain of the pRBC surface expressed
PfEMP1 molecule has been shown to be of central import-
ance for the virulence of the parasite. This domain is
involved in rosetting [15,19,24,30] and has recently been
Figure 6 Cross-reactivity of antibodies measured on the
recombinant protein in ELISA. IgG of goat immunized with IT4var60
(A), IT4var9 (B) and PAvarO (C) were tested for cross-recognition of
heterologous recombinant NTS-DBL1α domains by ELISA. 2μg of
recombinant IT4var60 (black dot), IT4var9 (red square), PAvarO
(blue triangle), TM284S2 (orange diamond) or His-tagged negative
control Sterile alpha motif (SAM) domain (black cross) were coated on
the plate and antibodies were assayed at two-fold serial dilution.
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with different rosetting-associated variants of the molecule
[46], therefore being a promising candidate in the develop-
ment of a vaccine against severe malaria. To efficiently de-
sign and test a vaccine it is important to understand if
different NTS-DBL1α variants of the DBL1α1 subtype can
induce consistent antibody responses in different animals.
In this study, the response to immunization with distinct
NTS-DBL1α domains in different animals was analysed
employing ELISA assays, live cell surface reactivity, epi-
tope prediction and peptide array.
PfEMP1-domains expressed by parasite strains with a
rosetting phenotype [19,24,25] were chosen for expression
of recombinant protein and animal immunizations. NTS-
DBL1α constructs of PAvarO and IT4var9 covered aa 1–
393 and refolded from inclusion bodies, for IT4var60
a longer construct was designed (aa 1–481), which was sol-
uble in E. coli. All proteins were monomeric and folded as
judged by mobility on non-reducing gel and size exclusion
profile (Figure 1). There were no differences detected as
both antibody titres and functionality was similar for
the antibodies generated against the different constructs
(Figures 2 and 3) suggesting that monomeric state and fold-
ing are sufficient requirements for potent induction of
biologically active antibodies. Further, epitopes elicited by
immunizations with different constructs were similar.
Previous studies showed induction of functional anti-
bodies towards NTS-DBL1α domains in mice and rabbits
[24,46,56] but no attempts has been made to compare in-
duction of antibodies in different animals regarding the
epitopes inducing or targeted by them.
All immunogens in the different animals, both species
and individuals, elicited a similar response when analys-
ing titres towards homologous proteins (Figure 2). This
is in contrast to what was previously reported for DBL
domains of the pregnancy malaria vaccine candidate
VAR2CSA where substantial differences were detected
when immunizing mice, rats and rabbits [57]. This could
be possibly explained by similar induction of B-cell epi-
topes in different species, as well as conservation of im-
munogenic features in the proteins studied herein.
When comparing predicted and recognized epitopes
substantial differences were found (Additional file 3). The
prediction method used for this analysis identified mainly
epitopes localized in the loop region of the molecule also
predicted to be surface exposed. However, analysis of pep-
tides that were in fact recognized revealed that also α-hel-
ical structures are predominant sites of immune responses.
The conserved and non-exposed LARSFADIG sequence,
present in SD2, was not predicted as highly immunogenic
but antibody responses were frequent and high in all ani-
mals, suggesting also that conserved parts of the molecule
are processed and presented on Major Histocompatibility
complex (MHC) molecules. The observations presented in
Figure 7 Cross-reactivity screening of antibodies measured on native protein on the pRBC surface. Analysis of surface reactivity of a panel
of 15 parasite strains or isolates with goat IgG or rat sera generated against NTS-DBL1α-domains of IT4var9, PAvarO, DBL1αS1.2var1, 3d7var5.2, PAvarO
(mixed) and DBL1αS1.2var1, 3d7var5.2, PAvarO (sequential). Empty squares: no reactivity; dark grey squares: reactivity of more than 10× above
background; grey squares: reactivity of 5-10× above background; light grey squares: reactivity of 2–5× above background nd: not done. Star
indicates parasites with a rosetting phenotype.
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ative; however, there might be a tendency for skewing to-
wards surface epitopes that are present in unstructured
loops. The analysis on epitopes recognized by immunized
animals suggests that it is more common to have epitopes
that span structured regions such as α-helices and that not
necessarily are surface exposed. The latter could be a mech-
anism of immune evasion by which parasites direct the im-
mune response towards epitopes that are not displayed on
the cell surface and therefore impede the labelling of the
pRBC with antibodies.
Analysis of the peptide array data for epitope recogni-
tion visualized substantial variation in between different
animals, despite their isogenicity. No clear consensus
was obtained when analysing different animal species
immunized with the same protein (Figure 5). In addition,
a limitation of this method is the fact that only linear
epitopes can be detected; possibly, conformational epi-
topes are predominant and account for equal potency
and efficiency of antibodies in different species. How-
ever, for both IT4var60 and IT4var9 there was a ten-
dency in different species to recognize different epitopes
in the N terminal part of the protein while more consen-
sus was present concerning epitopes in SD3 of DBL1α.
In this study, surface labelling of heterologous pRBC
with reagents against NTS-DBL1α-domains, did notreveal extensive cross-reactivity in heterologous parasite
strains. Cross-reactivity in ELISA appears much more
common for all three proteins analysed in the study. It has
been suggested that coating of antigens to plastic surfaces
as applied in ELISA-assays might unveil otherwise hid-
den epitopes [49,56]. When analysing epitopes cross-
recognized by goat IgG the conserved motif LARSFADIG
is consistently present. In addition, a peptide in the end of
h7 is cross-recognized by some goat IgG. This part of the
molecule has also previously been indicated as possible
site for generation of ELISA cross-reactive antibodies [52].
Cross-reactivity in ELISA strongly correlates with the
array cross-reactivity suggesting that most of it is due to
those epitopes. These results should be taken into consid-
eration when analysing cross-reactivity or sero-prevalence
relying solely on ELISA data: despite the fact that the re-
combinant domain is correctly folded it might expose
highly immunogenic epitopes that are not available in the
full length PfEMP1 presented on the erythrocyte surface.
Complementing ELISA with surface reactivity-data could
minimize false positive results.Conclusions
This study compares different animal species for their re-
sponse to immunization with distinct recombinant NTS-
Angeletti et al. Malaria Journal 2013, 12:32 Page 10 of 12
http://www.malariajournal.com/content/12/1/32DBL1α domains of the DBLα1 subclass. All variants are
able to elicit comparable titres of functional antibodies in
all animal species here tested. Targeted epitopes of these
antibodies are located in all subdomains of the NTS-DBL1α
proteins and some of them map to the conserved, internal
areas of the domain. Reactivity to epitopes on the homolo-
gous pRBC surface is strong; further, cross-reactivity be-
tween NTS-DBL1α-variants is common in ELISA and
peptide array while weak and infrequent with the live pRBC
surface of heterologous parasites.
The results show that NTS-DBL1α-domains display excel-
lent antigenicity and are able to induce antibodies targeting
adhesive events central to severe malaria in high titres. This
suggests that a combination of distinct DBL1α-domains in a
possible multimeric vaccine against severe malaria could
overcome the problem of low cross-reactivity.Additional files
Additional file 1: Analysis of epitope recognition by peptide
microarray. Results as seen in Figure 5, but organized according to
animal species, dividing goat (A) and rat (B) responses. IgG and sera were
tested for peptide recognition against the homologous sequences, on a
15-mers peptide array, of IT4var60 (black), IT4var9 (red) and PAvarO (blue).
Shown is the average of the individual animals immunized with the
same protein. Results are expressed as arbitrary absorbance units
normalized to the highest value set as 100%.
Additional file 2: Analysis of cross-recognition of epitopes on
peptide arrays by goat IgG. IgG of goat immunized with IT4var60
(black), IT4var9 (red) and PAvarO (blue) and non immune goat IgG
(green) were tested for peptide recognition against the heterologous
sequences on a 15-mers peptide array. Goat IgG were tested against
NTS-DBL1α sequences of IT4var60 (A), IT4var9 (B), PAvarO (C), TM284S2
(D) and 3D7var4 (E). Results are expressed as arbitrary absorbance units
normalized to the highest value set as 100%.
Additional file 3: Comparison of recognized versus predicted
epitopes. NTS-DBL1a sequences of IT4var60, IT4var9 and PAvarO with
highlighted peptide recognized by immunized animals in peptide
microarray (above a threshold of 30%) versus predicted epitopes (above a
value of 0.4 from the Bepipred server). Peptides recognized by rat
antibodies are coloured in orange, the ones recognized by goats in
purple while predicted epitopes are in red. Red boxes indicate consensus
recognition of the peptide by both rats and goats antibodies.Competing interests
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